The move towards value-based, personalized healthcare means that life science and pharma companies need to create conversations around evidence and efficiency, rather than traditional promotional materials.
Pharma can extend their value proposition by moving ‘beyond the pill’ and embracing an end-to-end (E2E) evidence tactic. This model involves providing evidence across the entire product life cycle.
Healthcare providers (HCPs) favour this model because it focuses on real world outcomes, providing them with trustworthy and authentic information. For more information on this visit our previous post and infographic explaining what HCPs want from pharma.